Mirae Asset Healthcare Fund vs Nippon India Nifty Pharma ETF
Direct Plan, Growth option · Data as on 30-10-2026
Mirae Asset Healthcare Fund is a Thematic fund and Nippon India Nifty Pharma ETF is a mutual fund. In the 3 years to 30-10-2026, Mirae Asset Healthcare Fund (Direct) returned 23.9% a year and Nippon India Nifty Pharma ETF (Direct) returned 22.9% a year. Mirae Asset Healthcare Fund charges 0.62% a year and Nippon India Nifty Pharma ETF 0.23% (Direct plans). Their portfolios overlap 63.9%: they hold 15 of the same securities.
Mirae Asset Healthcare Fund
Thematic
- 3 year return
- 23.9%
- Expense ratio
- 0.62%
- NAV
- ₹51.66
Nippon India Nifty Pharma ETF
- 3 year return
- 22.9%
- Expense ratio
- 0.23%
- NAV
- ₹27.89
Which is better, Mirae Asset Healthcare or Nippon India Nifty Pharma ETF? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Mirae Asset Healthcare returned more over 5 years: 16.6% a year against 14.9%.
- Mirae Asset Healthcare returned more over 3 years: 23.9% a year against 22.9%.
- Nippon India Nifty Pharma ETF costs less: 0.23% a year against 0.62% (Direct plans).
- Mirae Asset Healthcare swung less over 3 years: a standard deviation of 14.1% a year against 15.1%.
- Mirae Asset Healthcare fell less in its worst fall since 06-07-2021: −18.5% against −21.0%.
- Nippon India Nifty Pharma ETF holds more in large companies: 46.3% of the fund in large caps against 35.0%.
- Mirae Asset Healthcare is the larger fund: ₹3,494 Cr against ₹1,736 Cr.
- Their portfolios overlap 63.9%: 15 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Mirae Asset Healthcare Fund | Nippon India Nifty Pharma ETF |
|---|---|---|
| Fund house | Mirae Asset Mutual Fund | Nippon India Mutual Fund |
| Category | Thematic | Not available |
| AUM | ₹3,494 Cr (30-09-2026) | ₹1,736 Cr (30-09-2026) |
| NAV | ₹51.66 (Direct) | ₹27.89 (Direct) |
| Expense ratio (Direct) | 0.62% | 0.23% |
| Expense ratio (Regular) | 2.05% | Not available |
| Riskometer | Very High | Not available |
| Benchmark | BSE Healthcare TRI | Not available |
| Launch date | 02-07-2018 | Not available |
| Minimum investment | ₹5,000 | Not available |
| Lock in | None | Not available |
| Fund managers | Vrijesh Kasera, Tanmay Mehta | Not available |
| Exit load | If redeemed within 1 month (30 days) from the date of allotment: 1% If redeemed after 1 month (30 days) from the date of allotment: NIL | Not available |
Mirae Asset Healthcare vs Nippon India Nifty Pharma ETF: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Mirae Asset Healthcare Fund (Direct) | +1.18% | +0.66% | +14.13% | +18.44% | +23.86% | +16.63% | -- |
| Nippon India Nifty Pharma ETF (Direct) | +2.58% | +2.95% | +16.84% | +22.08% | +22.94% | +14.91% | -- |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | +11.62% | -- |
Category average: the average of the 235 Thematic funds, same plan type.
Mirae Asset Healthcare vs Nippon India Nifty Pharma ETF: Year-wise Returns
| Year | Mirae Asset HealthcareMirae Asset Healthcare | Nippon India Nifty Pharma ETFNippon India Nifty Pharma ETF |
|---|---|---|
| 2026to date | +20.52% | +19.82% |
| 2025 | −1.99% | −2.46% |
| 2024 | +41.20% | +39.59% |
| 2023 | +36.06% | +34.44% |
| 2022 | −10.47% | −10.86% |
| 2021 | +28.58% | -- |
Mirae Asset Healthcare vs Nippon India Nifty Pharma ETF: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of Mirae Asset Healthcare Fund
Rolling returns
Every 3-year holding period, 571 of them, one for each trading day from 08-07-2024 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Mirae Asset Healthcare Fund (Direct)
Nippon India Nifty Pharma ETF (Direct)
BSE Healthcare TRI
to
Sept 2024Feb 2022
to
Feb 2025Jun 2022
to
Jun 2025Nov 2022
to
Nov 2025Apr 2023
to
Apr 2026Aug 2023
to
Aug 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirae Asset Healthcare | 0.0 | 0.0 | 0.0 | 0.0 | 24.7 | 56.0 | 19.3 | 22.3% | 22.8% | 15.3% | 29.8% | 41% |
| Nippon India Nifty Pharma ETF | 0.0 | 0.0 | 0.0 | 3.8 | 39.6 | 52.2 | 4.4 | 20.3% | 20.5% | 12.3% | 27.7% | 0% |
| BSE Healthcare TRI | 0.0 | 0.0 | 0.0 | 2.1 | 18.4 | 52.0 | 27.5 | 22.9% | 23.5% | 13.9% | 28.8% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 06-07-2021. Past returns do not promise future returns.
Mirae Asset Healthcare vs Nippon India Nifty Pharma ETF: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 01-07-2021 to 30-10-2026: 64 instalments, ₹6,40,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Mirae Asset HealthcareMirae Asset Healthcare Fund (Direct) | ₹6,40,000 | ₹10,74,702 | ₹4,34,702 | 19.5% |
| Nippon India Nifty Pharma ETFNippon India Nifty Pharma ETF (Direct) | ₹6,40,000 | ₹10,43,720 | ₹4,03,720 | 18.4% |
Mirae Asset HealthcareMirae Asset Healthcare Fund (Direct)
Nippon India Nifty Pharma ETFNippon India Nifty Pharma ETF (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Mirae Asset Healthcare vs Nippon India Nifty Pharma ETF: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Mirae Asset Healthcare Fund (Direct) | Nippon India Nifty Pharma ETF (Direct) |
|---|---|---|
| Return (CAGR) | +18.44% | +22.08% |
| Standard deviation | 13.74% | 14.13% |
| Sharpe ratio | 0.96 | 1.19 |
| Sortino ratio | 1.43 | 1.86 |
| Maximum drawdown | −9.1% (23-10-2026) | −7.5% (01-02-2026) |
| Beta | 0.99 | 1.00 |
| Alpha | +6.18% | −0.28% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Mirae Asset Healthcare Fund (Direct) | Nippon India Nifty Pharma ETF (Direct) |
|---|---|---|
| Return (CAGR) | +23.86% | +22.94% |
| Standard deviation | 14.12% | 15.07% |
| Sharpe ratio | 1.26 | 1.12 |
| Sortino ratio | 1.80 | 1.63 |
| Maximum drawdown | −15.9% (28-02-2025) | −16.6% (28-02-2025) |
| Beta | 0.97 | 1.00 |
| Alpha | +1.28% | −0.30% |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Mirae Asset Healthcare Fund (Direct) | Nippon India Nifty Pharma ETF (Direct) |
|---|---|---|
| Return (CAGR) | +16.63% | +14.91% |
| Standard deviation | 13.69% | 14.93% |
| Sharpe ratio | 0.79 | 0.61 |
| Sortino ratio | 1.13 | 0.89 |
| Maximum drawdown | −18.5% (17-06-2022) | −17.7% (13-03-2023) |
| Beta | 0.95 | 1.00 |
| Alpha | +1.47% | −0.25% |
From daily NAVs, 29-10-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Mirae Asset Healthcare Fund (Direct) | Nippon India Nifty Pharma ETF (Direct) |
|---|---|---|
| Return (CAGR) | +21.71% | +13.22% |
| Standard deviation | 15.56% | 15.07% |
| Sharpe ratio | 1.06 | 0.50 |
| Sortino ratio | 1.54 | 0.72 |
| Maximum drawdown | −20.0% (23-03-2020) | −21.0% (13-03-2023) |
| Beta | 0.92 | 1.00 |
| Alpha | +5.56% | −0.26% |
From daily NAVs, 03-07-2018 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Mirae Asset Healthcare Fund (Direct)
Nippon India Nifty Pharma ETF (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Mirae Asset Healthcare Fund (Direct) | −18.5% | 03-01-2022 | 17-06-2022 | 11-07-2023 | 13 months | −2.8% |
| Nippon India Nifty Pharma ETF (Direct) | −21.0% | 04-10-2021 | 13-03-2023 | 27-07-2023 | 4 months | −0.3% |
| BSE Healthcare TRI | −21.6% | 15-09-2021 | 17-06-2022 | 20-07-2023 | 13 months | −3.8% |
From daily values since 06-07-2021, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Mirae Asset Healthcare Fund (Direct)
Nippon India Nifty Pharma ETF (Direct)
BSE Healthcare TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 3-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Mirae Asset Healthcare Fund (Direct)
Nippon India Nifty Pharma ETF (Direct)
BSE Healthcare TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 5-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Mirae Asset Healthcare Fund (Direct)
Nippon India Nifty Pharma ETF (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Mirae Asset Healthcare Fund (Direct) | 99% | 90% | 3.16% |
| Nippon India Nifty Pharma ETF (Direct) | 95% | 93% | 4.66% |
From month-end values since 06-07-2021. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Mirae Asset Healthcare vs Nippon India Nifty Pharma ETF: Portfolio Overlap
From each fund's latest monthly portfolio: Mirae Asset Healthcare Fund, September 2026; Nippon India Nifty Pharma ETF, September 2026
Holdings in common
- Overlap
- 63.9%
- Held by both
- 15
- Only in Mirae Asset Healthcare
- 15
- Only in Nippon India Nifty Pharma ETF
- 5
| Security | % of Mirae Asset Healthcare | % of Nippon India Nifty Pharma ETF |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 10.15% | 19.50% |
| Divi's Laboratories Ltd. | 9.79% | 11.97% |
| Torrent Pharmaceuticals Ltd. | 6.80% | 7.16% |
| Laurus Labs Ltd. | 5.51% | 7.82% |
| Dr. Reddy's Laboratories Ltd. | 4.84% | 7.62% |
| Aurobindo Pharma Ltd. | 3.78% | 4.69% |
| Glenmark Pharmaceuticals Ltd. | 4.78% | 3.56% |
| Alkem Laboratories Ltd. | 3.76% | 3.16% |
| IPCA Laboratories Ltd. | 3.39% | 2.71% |
| Cipla Ltd. | 2.63% | 7.68% |
| Gland Pharma Ltd. | 2.69% | 2.34% |
| Lupin Ltd. | 2.27% | 5.00% |
| Mankind Pharma Ltd. | 2.24% | 2.88% |
| Sai Life Sciences Ltd. | 3.23% | 2.14% |
| Biocon Ltd. | 2.00% | 2.62% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 63.9% means 63.9% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Mirae Asset Healthcare Fund
| Security | % of fund |
|---|---|
| Apollo Hospitals Enterprise Ltd. | 5.62% |
| Krishna Institute of Medical Sciences Ltd. | 3.39% |
| Aster DM Quality Care Ltd. | 3.32% |
| Onesource Specialty Pharma Ltd. | 3.01% |
| Fortis Healthcare Ltd. | 2.94% |
Largest holdings only in Nippon India Nifty Pharma ETF
| Security | % of fund |
|---|---|
| Zydus Lifesciences Limited | 2.92% |
| Wockhardt Limited | 1.77% |
| Ajanta Pharma Limited | 1.67% |
| Abbott India Limited | 1.43% |
| Piramal Pharma Limited | 1.30% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Mirae Asset Healthcare | Nippon India Nifty Pharma ETF |
|---|---|---|
| Equity | 100.0% | 99.9% |
| Debt | 0.0% | 0.0% |
| Cash and others | 0.0% | 0.1% |
Market cap of stocks
| Market cap | Mirae Asset Healthcare | Nippon India Nifty Pharma ETF |
|---|---|---|
| Large Cap | 35.0% | 46.3% |
| Mid Cap | 42.1% | 46.1% |
| Small Cap | 19.5% | 7.5% |
| Not on AMFI's list | 3.4% | 0.0% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Mirae Asset Healthcare | Nippon India Nifty Pharma ETF |
|---|---|---|
| Pharmaceuticals & Biotechnology | 75.8% | 99.9% |
| Healthcare Services | 20.5% | 0.0% |
| Chemicals & Petrochemicals | 1.9% | 0.0% |
| Healthcare Equipment & Supplies | 1.8% | 0.0% |
The six largest sectors of each fund's stocks, % of the fund.
Mirae Asset Healthcare vs Nippon India Nifty Pharma ETF: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Mirae Asset Healthcare Fund | Nippon India Nifty Pharma ETF |
|---|---|---|
| Total expense ratio (Direct) | 0.62% | 0.23% |
| Base expense ratio (Direct) | 0.45% | 0.18% |
| Total expense ratio (Regular) | 2.05% | Not available |
| Base expense ratio (Regular) | 1.66% | 0.00% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Mirae Asset Healthcare Fund vs Nippon India Nifty Pharma ETF: Frequently Asked Questions
What is the difference between Mirae Asset Healthcare Fund and Nippon India Nifty Pharma ETF?
Mirae Asset Healthcare Fund is a Thematic fund, Nippon India Nifty Pharma ETF is a mutual fund, run by Mirae Asset Mutual Fund and Nippon India Mutual Fund. Their portfolios overlap 63.9%. Mirae Asset Healthcare Fund charges 0.62% a year and Nippon India Nifty Pharma ETF 0.23%.
Which has given higher returns, Mirae Asset Healthcare Fund or Nippon India Nifty Pharma ETF?
Over 1 year: Mirae Asset Healthcare Fund +18.44%, Nippon India Nifty Pharma ETF +22.08%. Over 3 years: Mirae Asset Healthcare Fund +23.86% a year, Nippon India Nifty Pharma ETF +22.94% a year. Over 5 years: Mirae Asset Healthcare Fund +16.63% a year, Nippon India Nifty Pharma ETF +14.91% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Mirae Asset Healthcare Fund or Nippon India Nifty Pharma ETF?
Nippon India Nifty Pharma ETF charges less: 0.23% a year against 0.62%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Mirae Asset Healthcare Fund and Nippon India Nifty Pharma ETF overlap?
63.9%. They hold 15 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, TORNTPHARM. From each fund's latest monthly portfolio.
Which is better for SIP, Mirae Asset Healthcare Fund or Nippon India Nifty Pharma ETF?
Over the last 5 years, a monthly SIP of ₹10,000 from 01-10-2021 to 30-10-2026 grew to ₹10,11,191 in Mirae Asset Healthcare Fund (XIRR 20.0% a year) and ₹9,85,731 in Nippon India Nifty Pharma ETF (XIRR 19.0% a year). Both received 61 instalments. Past returns do not promise future returns.
Can I invest in both Mirae Asset Healthcare Fund and Nippon India Nifty Pharma ETF?
Yes. 63.9% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.